NEW YORK, Sept. 4-DiaDexus will support University of Michigan geneticist Samir Hanash in research using proteomic techniques to develop new biomarkers to diagnose and treat cancer, the company said today.
DiaDexus will provide research funding in exchange for exclusive licensing rights to discoveries of commercial interest. The University of Michigan also stands to receive milestone and royalty payments on any products developed out of the collaboration.
Hanash's research will focus on identifying cell surface membrane proteins as potential therapeutic targets or biomarkers. His team will analyze normal and cancerous biological samples and cell lines with a sensitive technique.
DiaDexus did not disclose the financial terms of the arrangement.